Xenetic Biosciences (XBIO) AI Stock Analysis

• Market Cap: $4.38M
• Dividend Yield: N/A
• Average Volume (3M): 8.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: -1.56%
• EPS Growth: 5.01%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -2.57
• Shares Outstanding: 1,542,139
• 10 Day Avg. Volume: 7,979
• 30 Day Avg. Volume: 8,819
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.07
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Xenetic Biosciences is currently facing substantial financial and operational challenges, as evidenced by its negative profitability and cash flow metrics. The technical analysis further supports a cautious outlook, with bearish indicators across key metrics. Valuation remains a concern due to the lack of earnings. However, the company's strong equity position and absence of debt offer some stability as it navigates these challenges.

Positive Factors

Clinical Development

The agreement with PeriNess accelerates DNase I based oncology program clinical development by leveraging PeriNess's expertise in drug development from preclinical to early-stage clinical programs.

Preclinical Results

Strong preclinical results show DNase I therapy can inhibit tumor growth and enhance survival in colorectal cancer models.

Strategic Collaborations

The Scripps Research Institute CAR-T collaboration has been extended, potentially generating meaningful preclinical data.

Negative Factors

Clinical Development Challenges

Xenetic continued to make progress in advancing its DNase-based technology toward Phase 1 clinical development for pancreatic carcinoma and other locally advanced or metastatic solid tumors.

Therapy Efficacy

These data suggest that DNase I administered in combination with CAR-T cells has the potential to bolster therapeutic responses in patients undergoing CAR-T cell therapy, particularly in solid tumors, an indication where CAR-T therapy efficacy has been limited.

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

How the Company Makes Money

Xenetic Biosciences makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves licensing its technologies to pharmaceutical partners, thereby earning milestone payments and royalties on the sales of drugs developed using its platforms. Xenetic also engages in collaborations and strategic partnerships to co-develop therapies, which may include upfront payments, research funding, and shared revenues from successful products. Additionally, the company may receive government grants and funding to support its research initiatives.

Xenetic Biosciences Financial Statement Overview

Summary

Overall, Xenetic Biosciences is grappling with profitability challenges, as reflected in its income statement and cash flow analysis. Despite a healthy equity position and no debt, the company must address its operational inefficiencies to improve profitability and cash flow generation. The financial stability from a strong balance sheet provides a foundation to support future growth initiatives.

Income Statement

Xenetic Biosciences has shown inconsistent revenue growth, with the latest annual revenue decreasing slightly by 1.6%. The gross profit margin remains strong at 100%, indicating efficient cost management relative to revenue. However, the company faces significant challenges with profitability, as evidenced by a negative net profit margin of -158.4% and consistent EBIT and EBITDA losses, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 87%. The company has no debt, which minimizes financial risk and provides stability. However, the return on equity is negative due to ongoing net losses, highlighting challenges in generating shareholder returns.

Cash Flow

Operating cash flow remains negative, indicating ongoing cash consumption in operations. The free cash flow also reflects a negative trend, although there is a slight improvement from the previous year. The cash flow to net income ratios are not favorable due to negative net income, suggesting struggles in translating operational activities into positive cash flows.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.50M	2.54M	1.71M	1.16M	436.94K
	Gross Profit
2.50M	2.54M	1.68M	1.13M	436.94K
	EBIT
-4.20M	-4.52M	-6.72M	-5.75M	4.55M
	EBITDA
-4.20M	-4.54M	-6.72M	-5.71M	-4.69M
	Net Income Common Stockholders
-3.96M	-4.13M	-6.39M	-5.54M	-10.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.17M	8.98M	13.10M	18.24M	11.53M
	Total Assets
6.90M	10.61M	14.72M	19.82M	13.18M
	Total Debt
0.00	0.00	0.00	27.04K	62.52K
	Net Debt
-6.17M	-8.98M	-13.10M	-18.22M	-11.47M
	Total Liabilities
894.26K	809.59K	1.07M	1.42M	963.97K
	Stockholders Equity
6.01M	9.80M	13.65M	18.39M	12.22M
Cash Flow		Free Cash Flow
-2.82M	-4.11M	-5.15M	-4.74M	-4.27M
	Operating Cash Flow
-2.82M	-4.11M	-4.65M	-4.74M	-4.27M
	Investing Cash Flow
0.00	0.00	-500.00K	0.00	0.00
	Financing Cash Flow
0.00	0.00	0.00	11.45M	5.43M

Xenetic Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Negative. The current price of 2.73 is above the 20-day moving average (MA) of 2.53, below the 50-day MA of 3.14, and below the 200-day MA of 3.80, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 81.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBIO.

Xenetic Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
TOVX	45 Neutral	$3.76M	―	-87.31%	―	―	6.87%
XBIO	43 Neutral	$4.38M	―	-50.12%	―	-1.56%	5.01%
JAGX	41 Neutral	$8.00M	―	-522.60%	―	19.75%	95.65%
KZIA	31 Underperform	$4.01M	―	-2639.52%	―	―	19.58%
OGEN	29 Underperform	$4.23M	―	-714.95%	―	-100.00%	76.55%

Xenetic Biosciences Corporate Events

Xenetic Biosciences Expands Collaboration for Cancer Treatment

Xenetic Biosciences has extended its collaboration with The Scripps Research Institute to further develop its DNase oncology platform. This initiative aims to enhance cancer treatment efficacy by targeting neutrophil extracellular traps, which promote cancer progression. The partnership focuses on combining DNase with CAR T-cell therapies, showing promise in preclinical studies for reducing tumor burden and improving therapeutic responses, with plans to advance towards clinical development for pancreatic and other solid tumors.